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ABSTRACT: Nature employs a limited number of genetically encoded axial ligands to control diverse heme enzyme activities. 
Deciphering the functional significance of these ligands requires a quantitative understanding of how their electron donating capa-
bilities modulate the structures and reactivities of the iconic ferryl intermediates compounds I and II. However, probing these rela-
tionships experimentally has proven challenging as ligand substitutions accessible via conventional mutagenesis do not allow fine 
tuning of electron donation and typically abolish catalytic function. Here we exploit engineered translation components to replace 
the histidine ligand of cytochrome c peroxidase (CcP) by a less electron donating Nδ-methyl histidine (Me-His) with little effect on 
enzyme structure. The rate of formation (k1) and the reactivity (k2) of compound I are unaffected by ligand substitution. In contrast, 
proton coupled electron transfer to compound II (k3) is 10-fold slower in CcP Me-His, providing a direct link between electron do-
nation and compound II reactivity which can be explained by weaker electron donation from the Me-His ligand (‘the push’) afford-
ing an electron deficient ferryl-oxygen with reduced proton affinity (‘the pull’). The deleterious effects of the Me-His ligand can be 
fully compensated by introducing a W51F mutation, designed to increase ‘the pull’ by removing a hydrogen bond to the ferryl-
oxygen. Analogous substitutions in ascorbate peroxidase (APX) lead to similar activity trends to those observed in CcP, suggesting 
a common mechanistic strategy is employed by enzymes using distinct electron transfer pathways. Our study highlights how non-
canonical active site substitutions can be used to directly probe and deconstruct highly evolved bioinorganic mechanisms.
Keywords: Heme enzyme, non-canonical ligand, metal-oxo reactivity, proton coupled electron transfer
  
INTRODUCTION 
In nature heme enzymes catalyze a wealth of oxidative trans-
formations. The axial ligand coordinating the heme iron varies 
across enzyme families and is pivotal to controlling catalytic 
function.1,2 Considerable effort has been devoted to under-
standing relationships between proximal ligand electron dona-
tion, the structures and reactivities of iconic ferryl intermedi-
ates compound I and compound II, and overall catalytic func-
tion.3-8 For example, the ability of cytochrome P450s and aro-
matic peroxygenases to functionalize unactivated C–H bonds 
is dependent upon axial thiolate ligation. Strong electron dona-
tion (‘the push’) from the cysteinate ligand increases electron 
density on the compound I ferryl-oxygen and thus enhances its 
reactivity with respect to C-H bond activation (‘the pull’).3-7  
Heme peroxidases utilize a histidine residue as the axial lig-
and to the heme iron, with a hydrogen bond formed between 
the non-coordinating Nδ atom and a conserved aspartate resi-
due (Figure 1a).1,9 This interaction imparts a degree of ‘imid-
azolate like’ character onto the axial ligand, thus increasing its 
electron donating capabilities. Despite extensive theoretical 
and experimental study,10,11 the significance of this imidazo-
late ligand in the peroxidase catalytic mechanism remains 
poorly understood, presenting a missing link in our under-
standing of heme biochemistry. Directly probing relationships 
between proximal ligand electron donation and heme enzyme 
reactivity has proven extremely challenging. Ligand substitu-
tions accessible through standard mutagenesis do not allow 
fine tuning of electron donating properties and typically elimi-
nate natural catalytic function.12 Efforts to install a greater 
range of ligands have often resorted to the creation of ‘cavity 
mutants,’ involving replacement of large ligands by amino 
acids with smaller side chains (Gly or Ala) and subsequent 
diffusion of exogenous ligands into the vacant co-ordination 
site. These studies have provided valuable insights into the 
roles of proximal heme ligands. However, the resulting ternary 
complexes typically fail to deliver catalysts with appreciable 
activity, demonstrating the importance of covalent attachment 
of ligands to the protein backbone.13,14 For example, coordina-
tion of imidazole to the H175G cavity mutant of cytochrome c 
peroxidase (CcP) fully restores its activity with hydrogen per-
oxide to generate a ferryl intermediate. However, the rate of 




Figure 1. Structure and catalytic mechanism of cytochrome c 
peroxidase (CcP). (a) The active site of CcP (PDB code: 
1ZBY).9 The hydrogen bond between Asp235 and His175 
imparts a degree of imidazolate like character onto the axial 
ligand, thus increasing its electron donating capabilities. (b) 
The catalytic cycle of CcP with its biological redox partner 
ferrous cytochrome c (cytc) as an electron donor. His52 is 
protonated in compound I but not the resting state.18 
plexation, making it challenging to exploit this approach to 
quantify the impact of ligand substitutions on compound I and 
compound II reactivity.14 
As a result researchers have turned to synthetic model com-
plexes, which offer greater versatility with respect to local 
metal co-ordination environment, to validate mechanistic hy-
potheses.2,15 However, the catalytic activities of these small 
molecule systems are typically orders of magnitude lower than 
enzymes, which possess highly evolved and sophisticated 
catalytic mechanisms which are not replicated in synthetic 
complexes. The ability to selectively install a greater repertoire 
of metal co-ordinating residues into proteins could therefore 
offer a powerful and more direct approach to probe complex 
bioinorganic mechanisms. Here we report the preparation and 
characterization of a functional cytochrome c peroxidase 
(CcP) with an Nδ-methyl histidine (Me-His) proximal ligand. 
In contrast to P450s where strong electron donation is linked 
to compound I reactivity,3-6 we show that ‘electron push’ from 
the ‘imidazolate like’ proximal ligand of CcP has little impact 
on compound I reactivity, and instead tunes the reactivity of 
compound II.  
RESULTS 
CcP recruits electrons from its biological redox partner fer-
rous cytochrome c (cytc) to reduce hydrogen peroxide in mito-
chondria.1 The reaction mechanism is comprised of three steps 
(Figure 1b); 1) reaction of the resting ferric enzyme with hy-
drogen peroxide to generate compound I, containing an oxi-
dized ferryl heme and a Trp191 radical cation,16 2) single elec-
tron reduction of compound I by ferrous cytc to generate com-
pound II and 3) single electron reduction of compound II by a 
second equivalent of ferrous cytc. Compound II reduction is 
coupled with proton transfer to the ferryl oxygen.17 The distal 
pocket His52, which is protonated in compound I but not in 
the resting state,18 is a likely source of the required proton. 
To probe the influence of proximal ligand electron donation 
on the CcP catalytic mechanism, the axial His175 ligand of S. 
cerevisiae CcP was replaced with a non-canonical Me-His 
residue using an engineered pyrrolysyl-tRNA synthe-
tase/pyrrolysl-tRNA pair (PylRSMe-His/tRNAPyl), which selec-
tively incorporates Me-His in response to the amber UAG stop 
codon (Figure S1).19 The CcP Me-His X-ray crystal structure, 
refined to a resolution of 1.90 Å (Figure S2, Table S1), super-
imposes well with a previously reported CcP His structure9 
(Figure 2, PDB code: 1ZBY, secondary structure superpose, 
RMS deviation of 0.11 Å). Comparison of the CcP His and 
CcP Me-His structures demonstrates that His → Me-His con-
stitutes a highly conservative mutation, with the geometry and 
environment of the heme cofactor and key active site residues 
well preserved in the modified enzyme. Arg48 within the dis-
tal pocket adopts two conformations as observed previously in 
ferric CcP (Figure 2).9 Proximal ligand substitution disrupts 
the conserved Asp-His proximal pocket hydrogen bond re-
sponsible for increasing the electron donating properties of His 
ligands in peroxidases.1,10-11 Asp235 undergoes a minor con-
formational adjustment to accommodate the additional methyl 
substituent on the proximal histidine ligand. The proximal Me-
His adopts a similar conformation to the histidine residue in 
previously reported structures, thus maintaining π-stacking 
interactions with Trp191. Significantly, the environment sur-  
 
 
Figure 2. Structural characterization of CcP His and CcP Me-
His. Overlay of CcP (PDB code: 1ZBY)9 and CcP Me-His 
(PDB code: 6H08) active sites (using secondary structure su-
perpose, RMS deviation of 0.107 Å). The CcP His heme co-
factor and key residues are shown as atom colored sticks with 
grey carbons. The protein backbone is represented in cartoon 
format (colored in grey). The CcP Me-His heme cofactor and 
key residues are shown as atom colored sticks with pink car-
bons. The protein backbone is represented in cartoon format 
(colored in pink). The 2Fo − Fc electron density map corre-




















rounding the redox active Trp191 residue is fully conserved in 
the CcP Me-His structure, including the hydrogen bonding 
interaction with Asp235 and interactions with nearby Met230 
and Met231 residues that are important for the stability of the 
compound I Trp191 radical cation.1 This contrasts with previ-
ous attempts to modulate proximal ligand electron donation in 
CcP though mutation of Asp235, which resulted in dramatic 
reorientation of the Trp191 residue.20 
Introduction of a proximal Me-His ligand resulted in a 22-
fold reduction in kcat for the oxidation of ferrous cytc from 
horse heart (pH 6.0, 25°C) (kcat = 805 ± 25 s−1 for CcP His, kcat 
= 38 ± 5 s−1 for CcP Me-His) with only modest changes in KM 
(Figure 3a and Table 1). Despite the reduction in kcat, CcP Me-
His is able to oxidize >10,000 equivalents of ferrous cytc with 
no evidence of enzyme deactivation. Mutation of the proximal 
pocket Trp191 residue to phenylalanine in CcP Me-His and 
CcP His eliminates catalytic activity, demonstrating that this 
redox active residue retains an essential role in the catalytic 
function of the modified enzyme. In contrast to the substantial-
ly reduced kcat observed with the biological redox partner fer-
rous cytc, proximal ligand substitution has minimal effects on 
the kinetics of guaiacol (ortho-methoxyphenol) oxidation 
(Figure S3b), suggesting that the non-canonical active site 
modification specifically perturbs long-range electron transfer 
from cytc mediated through Trp191.    







Figure 3. Kinetic and spectroscopic characterization of CcP 
His and CcP Me-His. (a) Michaelis-Menten plots of cytc oxi-
dation by CcP His (black, kcat = 805 ± 25 s−1, KMcytc = 18 ± 3 
µM) and CcP Me-His (red, kcat = 38 ± 5 s−1, KMcytc = 17 ± 2 
µM). Measurements at pH 6, 25°C, error bars are SEM n=3. 
(b) Overlay of the UV-vis spectra of the compound I states of 
CcP (black) and CcP Me-His (red). 
Table 1. Cytc oxidation kinetic parameters for CcP His, 
CcP Me-His and their W51F variantsa 
Variant kcat (s−1) KM (µM) 
CcP 805 ± 25 (590 ± 21)b 18 ± 3 (16 ± 2) 
CcP Me-His 38 ± 5 (25 ± 4) 17 ± 2 (18 ± 2) 
CcP W191F NDc - 
CcP W191F Me-His ND - 
CcP W51F 2,350 ± 100 14 ± 2 
CcP W51F Me-His 1,170 ± 30 18 ± 2 
aAll measurements were carried out at 25°C in potassium 
phosphate (50 mM) at pH 6.0. bValues in parentheses corre-
spond to measurements in D2O. cND: no activity detected 
above background.  
 
the midpoint reduction potential for the heme FeIII/FeII couple 
by +35 ± 1 mV (Figure S4), consistent with reduced electron 
donation from the proximal ligand.  This increased potential 
can be attributed to loss of a hydrogen bond between the prox-
imal ligand and Asp235. Despite this reduced electron dona-






Figure 4.  X-band continuous wave EPR spectra of the com-
pound I state of CcP His and CcP Me-His with and without the 
additional W51F mutation. EPR spectra recorded at 6 K show-
ing the effect of tryptophan-(indole-d5) on the spectra and a 
comparison with the CcP Me-His W191F variant; g values are 







pound I and compound II states are highly similar to the corre-
sponding spectra of the wild-type enzyme (Figure 3b, Figure 
S5 and Figure S6). The compound I and compound II states of 
CcP are not distinguishable by UV-vis spectroscopy, with 
spectral features consistent with a neutral ferryl heme (Soret 
maxima at 420 nm and associated Q bands at 530 and 560 
nm). 
In CcP His, the second oxidising equivalent of compound I 
is stored as a stable Trp191 radical cation, which is an essen-
tial intermediate along the electron transfer pathway from fer-
rous cytc.16 To confirm the identity of the protein based radical 
cation in CcP Me-His, compound I was characterized by X-
band cw EPR spectroscopy. CcP His compound I has previ-
ously been shown to produce a distinctive EPR signal at 10 K 
or below that arises from a distribution of scalar magnetic or 
exchange coupling (J) values between the S = 1 ferryl 
(FeIV=O) heme and the S = ½ tryptophan cation radical spin 
systems.16,21 That EPR signal was reproduced in our experi-
ments (Figure 4), having a shoulder at g = 2.04 and crossing 
point at g = 2.00 at 6 K. Global replacement of tryptophan 
residues in CcP His with L-tryptophan-(indole-d5) gave rise to 
changes in the EPR signal arising from hyperfine coupling to 
the Cβ-protons that are now resolved in the absence of the hy-
perine contributions from the indole ring protons. Additional-
ly, deuteration leads to a slight narrowing and shift of the 
shoulder at g = 2.04 due to a reduction in unresolved proton 
hyperfine coupling. These effects confirm the contribution 
made by the tryptophan cation radical to the compound I sig-
nal. This signal is present at 94-97% of heme concentration in 
the CcP His preparations as judged by double integration at 
non-saturating powers against Cu(II)-EDTA standards. The 6 
K compound I EPR signal associated with CcP Me-His (pre-
sent at 83-86% of heme concentration) lacks the shoulder at g 
= 2.04, however, L-tryptophan-(indole-d5) substitution gives 
rise to similar effects to those observed in CcP His, though 
naturally less dramatic on the narrower CcP Me-His signal. 
Spectra of CcP Me-His compound I bearing the W191F muta-
tion are consistent with the formation of relatively low yield-
ing (~15% of heme concentration) adventitious tyrosine radi-
cals remote from the heme, as previously observed in the 
W191F and W191G variants of CcP His.22,23 Therefore, de-





Figure 5. Pre-steady state kinetic characterization of CcP His and CcP Me-His. (a) The catalytic mechanism of CcP. (b) Observed 
rate constants for compound I formation at varying H2O2 concentrations. Representative kinetic traces at 20 µM H2O2 are shown 
(inset). A linear fit of kobs vs [H2O2] was used to derive a bimolecular rate constants of k1 = (3.5 ± 0.7) x 107 M-1 s-1 for CcP His 
(black) and k1 = (3.3 ± 0.4) x 107 M-1 s-1 for CcP Me-His (red). Error bars represent SD n=3. (c) Averaged kinetic traces (n=3) for 
compound I reduction for both CcP His (black) and CcP Me-His (red). Conditions: CcP His/CcP Me-His (4 µM), H2O2 (8 µM), 
delay time of 1 s before reaction with cytc (1.5 µM) (post-mixing concentrations).  Reactions were monitored by reduction in ab-
sorbance at 550 nm due to oxidation of ferrous cytc. These data are fitted to an integrated second order rate equation (grey lines) to 
derive an apparent intrinsic rate constants of k2 = (1.16 ± 0.12) x 108 M-1 s-1 in CcP His and k2 = (1.14 ± 0.25) x 108 M-1 s-1 in CcP 
Me-His. The instrument dead time for the determination of k2 is <1.5 ms. (d) Observed rate constants for compound II reduction at 
varying cytc concentrations.  Representative kinetic traces at 35 µM are shown (inset) and all data were fitted to: 𝐴!!" = 𝐴! +
𝛥𝐴 𝑒!!! !"#! !! + 𝑒!!!"#!  with k2 fixed to the value determined above. A linear fit of kobs vs. [cytc] was used to derive a bimolecu-
lar rate constants for CcP His (black, k3 = (2.7 ± 0.2) x 106 M-1 s-1) and CcP Me-His (red, k3 = (2.6 ± 0.1 x 105 M-1 s-1). Error bars 
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 5 
of CcP His, CcP Me-His forms a compound I characterized by 
a ferryl heme exchange-coupled to a Trp191 cation radical, 
with the differences in line shape being attributable to a 
change in that ferromagnetic coupling. Houseman et al21 state 
in their original determination of the value(s) of J for CcP His 
that ‘given the tiny energies associated with the heme-radical 
spin coupling, it is hardly surprising that the EPR spectrum of 
compound I should be exquisitely sensitive to small perturba-
tions in the protein’s surroundings.’  
Rate constants for the three elementary steps (k1, k2 and k3, 
Figure 5a) in the catalytic cycle of CcP His and CcP Me-His 
were determined at 4ºC using established stopped-flow tech-
niques.24 Introduction of the less electron donating Me-His 
ligand has negligible impact on the rate constant for com-
pound I formation (k1 = (3.5 ± 0.7) x 107 M-1 s-1 for CcP and k1 
= (3.3 ± 0.4) x 107 M-1 s-1 for CcP Me-His, Figure 5b, Figure 
S7a-d and S7i). Likewise, the rate constant for compound I 
reduction is unaffected by proximal ligand substitution (k2 = 
(1.16 ± 0.12) x 108 M-1 s-1 in CcP His and k2 = (1.14 ± 0.25) x 
108 M-1 s-1 in CcP Me-His, Figure 5c and Figure S7l), demon-
strating that the natural electron transfer pathway from ferrous 
cytc to Trp191 is maintained in the modified enzyme and that 
the redox potential of Trp191 has not been significantly al-
tered by axial ligand substitution. In contrast, compound II 
reduction is 10-fold slower in CcP Me-His (k3 = (2.6 ± 0.1) x 
105 M-1 s-1 vs (2.7 ± 0.2) x 106 M-1 s-1 for CcP His, Figure 5d, 
Figure S7e-h and S7j). This 10-fold reduction in k3 also corre-
lates with a comparable reduction in kcat in steady-state assays 
at 4ºC (kcat = 235 ± 35 s−1 for CcP His, kcat = 22 ± 5 s−1 for CcP 
Me-His, Figure S3c and S3d). 
The relationship between axial ligand substitution and com-
pound II reactivity cannot be rationalized through considera-
tion of the driving force for electron transfer, which is greater 
in CcP Me-His due to the increase in heme redox potential. 
However, differences in electronic coupling between Trp191 
and the heme center upon ligand substitution could potentially 
give rise to reduced electron transfer rates due to modulation 
of the electron transfer pathway. Alternatively, compound II 
reduction in heme peroxidases is thought to be coupled to 
proton transfer to the ferryl oxygen, with significant solvent 
kinetic isotope effects (KSIEs) reported previously for ascor-
bate peroxidase and Leishmania peroxidase (LmP).25,17 The 
less electron-donating Me-His ligand could give rise to a less 
basic ferryl-oxygen and consequently perturb proton coupled 
electron transfer to the ferryl heme (Figure 6c and Figure 6d). 
The pKa of metal-oxo bonds is known to be exquisitely sensi-
tive to the electron donating capabilities of ancillary ligands.26  
To distinguish between these two mechanistic hypotheses, 
we performed activity assays in buffered H2O and D2O. Kinet-
ic characterization of CcP His and CcP Me-His (pH/pD 6.0) 
revealed a KSIE of 1.4 and 1.5, respectively, with no effect on 
KM in either variant (Figure 6a). We also investigated the in-
fluence of pH/pD on CcP His and CcP Me-His activity. For 
both variants, initial reaction velocities increase with decreas-
ing pH/pD between 6 and 5 (Figure S8a and S8b). The in-
creased reaction rates also correlate with increasing KSIEs  
 
 
Figure 6. Solvent kinetic isotope effects and the role of Trp51 in controlling compound II proton affinity and reactivity. (a) Bar 
chart showing the solvent kinetic isotope effect on kcat for cytc oxidation by CcP His, CcP Me-His  at pH/pD = 6 and at pH/pD = 5. 
CcP His: KSIE = 1.4 (pH/pD = 6) and KSIE = 2.2 (pH/pD = 5) . CcP Me-His: KSIE = 1.5 (pH/pD = 6) and KSIE = 2.1 (pH/pD = 
5) (b) Bar chart showing the kinetics (kcat) of cytc oxidation by CcP His, CcP Me-His and their W51F variants. (c-e) Schemes for 
proton coupled compound II reduction in (c) CcP His, (d) CcP Me-His and (e) CcP Me-His W51F, highlighting the importance of 
axial ligand electron donation (the ‘push’) and hydrogen bonding interactions with Trp51 in controlling the proton affinity of the 
ferryl oxygen (the ‘pull’). The proton (“H”) is likely transferred from His52 via an ordered water molecule.17 
a b 
c d e 
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Figure 7. Kinetic characterization of ascorbate peroxidase 
(APX) and key active site mutants. (a) The active site of APX 
showing the substrate ascorbate bound at the γ-heme edge 
(PDB code: 1OAF).31 (b) Bar chart showing the kinetics (kcat) 
of ascorbate oxidation by APX His, APX Me-His and APX 
Me-His W51F. Measurements are recorded at 25°C in phos-
phate buffer (50 mM, pH 6).   
 
across the series, with values of 2.2 and 2.1 determined for 
CcP His and CcP Me-His, respectively, at pH/pD = 5 (Figure 
6a). These data demonstrate that proton transfer is involved in 
rate limiting compound II reduction in CcP His and CcP Me-
His, and suggest that the observed electron donation-
compound II reactivity trend can be explained by considering 
the proton affinity (‘the pull’) of the ferryl-oxygen (Figure 6c 
and 6d). 
We therefore considered alternative factors that are likely to 
govern the pKa of compound II. The N-H group of Trp51 
forms a hydrogen bond to the ferryl oxygen,18 an interaction 
that can be expected to withdraw electron density from the 
Fe(IV)=O unit. We reasoned that deletion of this hydrogen 
bond using a W51F mutation in CcP His and Me-His would 
provide a means of increasing the pKa of the ferryl oxygen 
without causing significant disruption of the electron transfer 
pathway from Trp191 to the heme iron. Indeed, EPR spectra at 
6 K of compound I generated in W51F CcP and W51F CcP 
Me-His demonstrate formation of a ferryl heme:Trp191 ex-
change coupled species (Figure 4). Consistent with previous 
studies,27 a W51F mutation in CcP His leads to a 3-fold in-
crease in cytc oxidation activity (kcat = 2,350 ± 100 s-1). This 
activity has been previously been shown to be strictly depend-
ent on the presence of Trp191, demonstrating that the natural 
electron transfer pathway is maintained in the W51F mutant.28 
The W51F substitution in CcP Me-His leads to a more dra-
matic 32-fold increase in kcat (1,170 ± 30 s-1, ferrous cytc oxi-
dation) (Figure 6b, 6e and Figure S3f). Thus the deleterious 
effects of reduced electron donation from the Me-His axial 
ligand can be fully compensated by removing a single hydro-
gen bonding interaction to the ferryl oxygen (Figure 6d and 
6e) to afford a variant (W51F CcP Me-His) with catalytic fea-
tures reminiscent of the wild-type enzyme, further underscor-
ing the importance of Fe(IV)=O pKa in governing compound 
II reactivity. 
A strongly electron donating ‘imidazolate-like’ axial ligand 
is a conserved feature across the heme peroxide family. To 
investigate whether this ligand plays an important role in tun-
ing Fe(IV)=O pKa and catalytic activity in family members 
other than CcP, we elected to re-engineer the heme coordina-
tion environment of ascorbate peroxidase (APX). We have 
previously shown that introducing a Me-His ligand into an 
evolved ascorbate peroxidase (APX2) has negligible effects on 
the efficiency of guaiacol oxidation, but increases the robust-
ness of the enzyme towards irreversible deactivation during 
catalysis.29 The active site structure and overall catalytic 
mechanism of APX is highly similar to that of CcP. Com-
pound II reduction is rate-limiting,30 and electron transfer from 
ascorbate is thought to be coupled with proton transfer to the 
ferryl-oxygen.25 However, unlike CcP, the proximal pocket 
Trp179 of APX does not participate in redox chemistry and 
electron transfer to the heme occurs directly from the small 
molecule substrate ascorbate bound at the γ-heme edge (Figure 
7).31 Consequently, we reasoned that axial ligand substitution 
in APX would provide a means of tuning Fe(IV)=O pKa with-
out causing significant perturbations to the pathway of elec-
tron transfer from substrate to the heme center. His → Me-His 
ligand substitution in APX leads to a substantial reduction in 
kcat for ascorbate oxidation (pH 6.0, 25°C) (kcat = 270 ± 71 s−1 
for APX His, kcat = 66 ± 13 s−1 for APX Me-His, respectively) 
with negligible changes in KM (Figure 7, Fig S9). We have 
previously shown that this substitution causes only minor 
structural changes similar to those observed in CcP.29 Signifi-
cantly, the activity of APX Me-His can be restored to wild-
type levels by introducing a W41F substitution designed to 
increase Fe(IV)=O pKa (kcat = 234 ± 12 s−1 for APX Me-His 
W41F). These activity trends mirror the trends observed in 
CcP (Figure 6b), suggesting a common mechanistic strategy is 
employed by enzymes using distinct electron transfer path-
ways. Combined, these data provide further evidence of the 
relationships between Fe(IV)=O basicity and reactivity. 
DISCUSSION 
The ability to expand upon nature’s genetic code to selec-
tively install non-canonical ligands into proteins provides ex-
citing new opportunities to directly probe metalloenzyme 
mechanisms.32 For example, selenocysteine has proven to be a 
valuable surrogate for axial heme thiolate ligands.33-35 We 
have recently demonstrated that introduction of a Me-His 
proximal ligand into an evolved ascorbate peroxidase 
(APX2)29 and into the oxygen binding protein myoglobin36 
improves catalytic performance towards non-biological oxida-
tions of model phenolic substrates.  
An expanded genetic code has now allowed us to elucidate 
the functional significance of the ‘imidazolate like’ axial lig-
and of a heme peroxidase. Replacement of the proximal histi-
dine ligand of CcP by Me-His provides a means of disrupting 
the hydrogen bond between Asp235 and the axial histidine 
while preserving catalytic function and crucially, the environ-
ment surrounding the key redox active Trp191 residue. This 
contrasts with previous attempts to modulate proximal ligand 
electron donation though mutation of Asp235, which resulted 
in dramatic reorientation of the Trp191 residue and complete 
loss of activity.20 Surprisingly, replacement of the His ligand 
by Gln has previously been shown to have little effect on the 
rate of cytc oxidation.37 However, whilst a W191F mutation in 
CcP His or CcP Me-His abolishes activity, the CcP H175Q 
W191F double mutant maintains high levels of activity. The 
H175Q mutation thus appears to open up alternative electron 
pathways from cytc to the ferryl heme of CcP that are not uti-
lized in the natural catalytic cycle. 
The availability of a functional CcP with a modified axial 
ligand allowed us to directly probe and quantify the impact of 
altered ligand electron donation on the reactivity of the iconic 
ferryl intermediates compound I and compound II. Replace-










donating Me-His has little effect on the rate of formation of 
compound I. This contrasts with the substantial increase in rate 
constant for the formation of ferryl intermediates observed 
upon His → Me-His ligand substitution in myoglobin36 an 
oxygen binding protein that has served as a valuable model 
system to probe heme enzyme structure-function relationships. 
Introduction of the Me-His ligand into CcP also has negligible 
effects on the rate constant for compound I reduction, demon-
strating that the natural electron transfer pathway from ferrous 
cytc to Trp191 is maintained in the modified enzyme. In con-
trast, compound II reduction is 10-fold slower in CcP Me-His, 
providing a direct link between axial ligand electron donation 
and compound II reactivity. Our combined data present a 
compelling body of evidence in support of Fe(IV)=O pKa be-
ing a key determinant of compound II reactivity in heme pe-
roxidases, with reduced electron donation from the non-
canonical Me-His ligand (‘the push’) affording an electron-
deficient ferryl-oxygen with decreased proton affinity (‘the 
pull’) compared with the wild-type enzyme. The deleterious 
effects of the Me-His ligand can be fully compensated by in-
troducing a W51F mutation, designed to increase ‘the pull’ by 
removing a hydrogen bond to the ferryl-oxygen. This ability to 
rationally rewire the catalytic machinery of CcP NMH pro-
vides strong evidence to support our mechanistic interpreta-
tions. The W51F mutation in CcP His has previously been 
shown to increase the reactivity of the ferryl heme center. 
However, the molecular origins of this increased reactivity are 
not well defined. For example, it has been suggested that in-
troduction of the smaller Phe residue provides more space and 
flexibility in the heme pocket that could give rise to the ob-
served activity changes.38 Elsewhere, the increased rate of 
compound II reduction has been ascribed to an increase in 
activation entropy, which the authors suggest may arise due to 
a more facile release of the ferryl oxygen atom as water.39 We 
instead propose that the W51F substitution serves to facilitate 
proton transfer to the ferryl oxygen, which is required prior to 
the dissociation of water. This interpretation is consistent with 
the large increase in cyt c oxidation activity due to W51F mu-
tation in CcP Me-His, and the substantial kinetic solvent iso-
tope effects observed for CcP His and CcP Me-His.    
In summary, this study sheds light on long standing ques-
tions in heme biochemistry and advances our fundamental 
understanding of biological electron transfer events. Proton 
coupled electron transfers and related H atom transfers to high 
valent metal-oxo intermediates are thought to be ubiquitous in 
biological systems, and have been implicated as key steps in 
the catalytic mechanisms of several histidine ligated metal-
loenzymes.40,41 Our methodology is thus expected to provide a 
versatile strategy to deconstruct these complex and sophisti-
cated bioinorganic mechanisms and can be extended to probe 
and tune the reactivities of isoelectronic heme carbene and 
nitrene intermediates.42 Such insights into the subtle interplay 
between active site structure and catalytic activity will be criti-
cal for future efforts to rationally create functional metalloen-
zymes. 
EXPERIMENTAL PROCEDURES 
Materials. All materials were obtained from Sigma-Aldrich 
unless otherwise stated. Oligonucleotides were synthesized by 
MWG Eurofins (Ebersberg, Germany).  Ferric cytc from horse 
heart was obtained from Sigma-Aldrich and used throughout 
the study.  
Construction of pET-11a_CcP, pET-11a_CcP_Me-His and 
their variants. The gene encoding cytochrome c peroxidase 
(Ccp1p from the S. cerevisiae YJM1444 genome) was PCR 
amplified from plasmid pLeics03CCP39 (a modified version 
of an original CcP clone)43 using Phusion High-Fidelity DNA 
polymerase (New England BioLabs, UK). Primers contained a 
N-terminal His tag and complimentary sequences to allow 
insertion of the PCR product into pET-11a plasmid using In-
Fusion® Advantage PCR Cloning via NdeI and BamHI re-
striction sites, yielding pET-11a_CcP.  The His175Me-His 
mutation was introduced into the pET-11a_CcP by replacing 
the His175 codon with a TAG stop codon.  Site-directed mu-
tagenesis using the Q5® Site-Directed Mutagenesis Kit (New 
England BioLabs, UK) of pET-11a_CcP yielded pET-
11a_CcP_Me-His.  W191F and W51F mutations were intro-
duced into pET-11a_CcP and pET-11a_CcP_Me-His using the 
Q5® Site-Directed Mutagenesis Kit.  Correct DNA sequences 
were confirmed by DNA sequencing (MWG Eurofins).  
Construction of pET-29b_APX, pET-29b_APX _Me-His. 
An engineered monomeric soybean ascorbate peroxidase 
(APX) containing K14D, E112K and A134P mutations was 
used throughout this study.44 We have previously created the 
p29b_APX2 and p29b_APX2_Me-His constructs required for 
the production of APX W41F and APX Me-His W41F, re-
spectively.29 To create pET-29b_APX and pET-29b_APX Me-
His, a F41W mutation was introduced into p29b_APX2 and 
p29b_APX2_Me-His using assembly PCR followed by re-
striction cloning using NdeI and XhoI sites.  
Protein production and purification. For expression of CcP 
and its variants, BL21(DE3) E. coli were transformed with 
pET-11a_CcP, pET-11a_CcP_W51F and pET-
11a_CcP_W191F and the cells were plated onto LB agar 
(Formedium, Norfolk, UK) plates containing 50 µg/ml ampi-
cillin. For expression of APX, BL21(DE3) E. coli was trans-
formed with pET-29b_APX and the cells were plated onto LB 
agar (Formedium, Norfolk, UK) plates containing 50 µg/ml 
kanamycin. A single colony of freshly transformed cells was 
cultured for 18 h in 10 ml of LB medium containing 50 µg/ml 
ampicillin or kanamycin (for CcP and APX, respectively). 4 
ml of the culture was used to inoculate 400 ml of 2xYT medi-
um (Formedium, Norfolk, UK) supplemented with 1 mM δ-
aminolevulinic acid and 50 µg/ml of the appropriate antibiotic.  
The culture was incubated for ~2 h at 37°C with shaking at 
180 rpm. When the OD600 of the culture reached ~0.5, IPTG 
was added to a final concentration of 100 µM. The induced 
cultures were incubated for ~20 h at 25°C, and the cells were 
subsequently harvested by centrifugation at 7000 g for 10 min. 
For expression of CcP Me-His and its variants, BL21(DE3) 
E. coli were co-transformed with pET-11a_CcP_Me-His/ 
pET-11a_CcP_Me-His_W191F/pET-11a_CcP_Me-His_W51F 
and pEVOL_PylRSMe-His29 and the cells were plated onto 
LB agar plates containing 50 µg/ml ampicillin and 34 µg/ml 
chloramphenicol. For expression of APX Me-His and APX 
Me-His W41F, BL21(DE3) E. coli were transformed with 
pET-29b_APX Me-His and p29b_APX2_Me-His and the cells 
were plated onto LB agar (Formedium, Norfolk, UK) plates 
containing 50 µg/ml kanamycin and 34 µg/ml chlorampheni-
col. A single colony of freshly transformed cells was cultured 
for 18 h in 10 ml of LB medium containing 50 µg/ml ampicil-
lin or kanamycin (for CcP and APX, respectively) and 34 
µg/ml chloramphenicol. 4 ml of the culture was used to inocu-
late 400 ml of 2xYT medium supplemented with 1 mM δ-
aminolevulinic acid, 10 mM H-His(3-Me)-OH (Me-His) 
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(Bachem, Saint Helens, UK), 50 µg/ml of the appropriate anti-
biotic and 34 µg/ml chloramphenicol. The culture was incu-
bated for ~2.5 h at 37°C with shaking at 180 rpm. When the 
OD600 of the culture reached ~0.5, IPTG and arabinose were 
added to a final concentration of 100 µM and 0.05%, respec-
tively.  The induced cultures were incubated for ~20 h at 
25°C, and the cells were subsequently harvested by centrifuga-
tion at 7000 g for 10 min.  
The pelleted bacterial cells were suspended in phosphate 
buffer (50 mM KPi, 300 mM NaCl, 10 mM imidazole pH 7.5) 
supplemented with lysozyme (1 mg/ml), DNase (0.1 U/ml) 
and a Complete EDTA free protease inhibitor cocktail tablet 
(Roche) and subjected to sonication (13 mm probe, 15 mins, 
20 s on, 40 s off, 40% amplitude).  Cell lysates were centri-
fuged at 27,000 g for 30 min and the supernatants subjected to 
affinity chromatography using Ni-NTA Agarose (Qiagen, 
West Sussex, UK). His-tagged CcP and APX variants were 
eluted by 50 mM KPi, 300 mM NaCl, pH 7.5 buffer contain-
ing 300 mM imidazole. The purified protein was desalted us-
ing a 10DG desalting column (Bio-Rad, Hertfordshire, UK) 
into 50 mM KPi pH 6 buffer.  To maximize heme occupancy, 
variants were reconstituted with hemin chloride.  Cell suspen-
sions were mixed with 0.5 mM of hemin chloride (50 mM 
stock solution in 10 mM NaOH) for 30 mins at RT and filtered 
through a 0.45 micron membrane.  The CcP and CcP Me-His 
variants were then subjected to anion exchange chromatog-
raphy with 50 mM KPi pH 6 buffer using a ResourceTM Q 
column on an AKTA Fast Protein Liquid Chromatography 
(FPLC) system (both GE Healthcare, Buckinghamshire, UK).  
Proteins were eluted by a linear gradient of NaCl in the con-
centration range 0-500 mM and the eluate was collected in 2 
ml fractions. The purest fractions were selected after spectral 
analysis, pooled and concentrated using Vivaspin 20 centrifu-
gal concentrators (Generon, Berkshire, UK) with a 10 kDa 
molecular weight cut off membrane. The protein was aliquot-
ed, flash frozen in liquid nitrogen and stored at -80°C.  The 
concentrations of CcP and APX proteins were determined 
assuming an extinction coefficient of 101 mM-1 cm-1 at 408 
nm and 128 mM-1 cm-1 at 405 nm, respectively.2,29 The heme 
occupancies of purified proteins and their variants are compa-
rable, with similar Rz (A410/A280) values of ~1.5. 
Production of CcP and CcP Me-His containing L-
tryptophan-(indole-d5). For expression of L-tryptophan-
(indole-d5) CcP (d-Trp CcP) and L-tryptophan-(indole-d5) CcP 
Me-His (d-Trp CcP Me-His); BL21(DE3) E. coli were trans-
formed with pET-11a_CcP or pET-11a_CcP_Me-His   and 
pEVOL_PylRSMe-His, respectively, and single colonies were 
cultured for 18 h in 10 ml of LB medium containing the ap-
propriate antibiotics. 2 ml of the culture was used to inoculate 
200 ml of M9 minimal medium; containing 33.7 mM 
Na2HPO4, 22.0 mM KH2PO4, 8.55 mM NaCl, 9.35 mM 
NH4Cl, 0.4% glucose, 1 mM MgSO4, 0.3 mM CaCl2, 1 µg/L 
biotin and 1 µg/L thiamin, 1 x trace elements solution (100 x 
trace element solution - 13.4 mM EDTA, 3.1 mM FeCl3-
6H2O, 0.62 mM ZnCl2, 76 µM CuCl2-2H2O, 42 µM CoCl2-
2H2O, 162 µM H3BO3, 8.1 µM MnCl2-4H2O), 0.08% –Trp 
DROP OUT Complete Supplement Mixture (ForMedium) and 
10 mM L-tryptophan-(indole-d5).  Cultures were induced and 
pelleted as above and the proteins were purified as described 
above. Complete replacement of all tryptophans with L-
tryptophan-(indole-d5) was confirmed by MS (Figure S1). 
MS analysis. Purified protein samples were buffer-exchanged 
into 0.1% acetic acid using a 10K MWCO Vivaspin (Sartori-
us) and diluted to a final concentration of 0.5 mg ml-1. MS was 
performed using a 1200 series Agilent LC, 5 µl injection into 
5% acetonitrile (with 0.1% formic acid) and desalted inline for 
1 min. Protein was eluted over 1 min using 95% acetonitrile 
with 5% water. The resulting multiply charged spectrum was 
analyzed using Agilent QTOF 6510 and deconvoluted using 
Agilent MassHunter Software. All data is presented in Figure 
S1. 
Crystallization, refinement and model building. CcP Me-
His was crystallized at 50 mg ml−1 in 50 mM KPi, pH 6 buffer. 
Initial crystallization conditions were identified using the 
JCSG+ matrix screen (Molecular dimensions). Crystals suita-
ble for diffraction experiments were obtained by sitting drop 
vapour diffusion at 4°C in 400 nl drops containing equal vol-
umes of protein and a solution containing 5 mM cobalt(II) 
chloride hexahydrate, 5 mM cadmium chloride 
hemi(pentahydrate), 5 mM magnesium chloride hexahydrate, 
5 mM  nickel(II) chloride hexahydrate, 0.1 M HEPES pH 7.5 
and 12% w/v PEG 3350.  The crystals were cryoprotected by 
the addition of 10% PEG 200 to the mother liquor and flash-
cooled in liquid nitrogen. Data were collected on beamline 
IO4-1 (wavelength 0.9159 Å) at the Diamond Light Source 
Facility and reduced and scaled with the X-ray Detector Soft-
ware suite (XDS37). The CcP Me-His crystal structure was 
determined by molecular replacement using the PHASER 
program in the CCP4 suite45 using WT CcP structure as the 
starting model (PDB code: 2CYP). The CcP Me-His model 
was completed by iterative cycles of manual model building 
and real space refinement using the program Coot and crystal-
lographic refinement using Refmac. The processing and final 
refinement statistics are presented in Table S1.  Coordinates 
and structure factors have been deposited in the Protein Data 
Bank under accession number 6H08. 
Spectroscopic characterization of CcP and CcP Me-His 
variants. UV-vis absorption analysis was carried out on a 
Cary 50Bio UV-vis spectrophotometer (Varian, CA, USA), 
using a 1 cm path length quartz cuvette, recording spectra 
between 250 and 700 nm and typically with CcP at 4 µM in 50 
mM KPi pH 6 buffer (See Figure S5). 
Steady state enzyme kinetic assays. Steady state enzyme 
assays were carried out on a Cary 50Bio UV-vis spectropho-
tometer (Varian, CA, USA) in 50 mM KPi pH 6 using a 1 cm 
path length, 1 ml quartz cuvette.  For cytc oxidation assays 
CcP, CcP W51F, CcP Me-His, and CcP W51F Me-His vari-
ants were diluted to 1.0 µM on the basis of the heme absorp-
tion, respectively. CytcII was prepared by reduction with di-
thionite and the excess reductant was removed with a 10DG 
desalting column.  The concentration of cytcII was calculated 
using the extinction coefficient; ε550 = 27.7 mM-1 cm-l.44 At 
each concentration of cytc (0–100 µM), CcP, CcP W51F, CcP 
Me-His, and CcP W51F Me-His variants were diluted to 1, 1, 
10, and 1 nM, respectively. H2O2 (100 µM) was added to initi-
ate the reaction and the rate of change in absorbance at 550 nm 
was monitored over 1 min at 25°C.  The difference in absorp-
tivity of cytcII and cytcIII was calculated using Δε550= 19.5 
mM-l cm-l.46 Reactions were performed in triplicate (at RT and 
4°C) to produce a mean rate calculated as moles of cytcII oxi-
dized per mol CcP per second. These data were plotted against 
the relevant cytcII concentration and fitted using the Michae-
lis–Menten hyperbolic function within Origin software. Re-
ported values are corrected for background cytc oxidation in 
the absence of enzyme.  For CcP His W191F and CcP W191F 
Me-His at 50 nM no activity was observed above background. 
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For ascorbate oxidation assays APX, APX Me-His and APX 
Me-His W41F variants were diluted to 1 µM on the basis of 
the heme absorption, respectively. At each concentration of 
ascorbate (0–1100 mM), APX, APX Me-His and APX Me-His 
W41F variants were diluted to 1 nM and 100 µM H2O2 was 
added to initiate the reaction.  Product formation was moni-
tored at 290 nm over 5 min at 25°C and calculated using ε290= 
2.8 mM-l cm-l.47 All reactions were performed in triplicate to 
produce a mean rate calculated as moles of substrate oxidized 
per mol APX per second. These data were plotted against the 
relevant substrate concentration and fitted using the Michae-
lis–Menten hyperbolic or Hill functions within Origin soft-
ware (see Figure S9). 
Redox potentiometry. Optically transparent thin layer elec-
trochemistry (OTTLE) techniques were used to determine the 
CcP heme redox potentials.48,49 Briefly, the proteins were ex-
changed into 100 mM KCl, 50 mM potassium phosphate, 10% 
glycerol, pH 6, and the following redox mediators were added 
to ensure efficient equilibration in the electrochemical cell: 20 
µM anthroquinone-2-sulfonate, 20 µM phenazine, 25 µM 2-
hydroxy-1,4-naphthoquinone and 6 µM indigotrisulfonate. The 
solution containing protein and mediators was added to a 
home-built OTTLE cell, constructed from a flat quartz EPR 
cell (Wilmad, USA) calibrated against cytc, a platinum gauze 
working electrode, platinum counter electrode and an 
Ag/AgCl reference electrode (BASi, USA). Potentials were 
applied for 30 minutes each across the cell using a Biologic 
SP-150 potentiostat, and titrations were carried out in both 
reductive and oxidative directions to ensure good equilibra-
tion. UV/visible spectra were acquired at each potential using 
an Agilent Cary 60 UV/visible spectrometer. Heme redox 
potential was determined by plotting the absorbance at 439 nm 
(corresponding to the ferrous heme Soret band) against applied 
potential and fitting to a standard 1-electron Nernst function: 
𝑓 𝑥 =  𝐴 + 𝐵 × 10 !"!! !" 1 + 10 !"!! !" . 
Where A and B are the y-axis values representing 0 and 100% 
reduced CcP respectively. Em corresponds to the heme reduc-
tion potential. Once it was established that the Em for both 
reductive and oxidative titrations was the same, the data was 
combined and plotted as proportion reduced vs applied poten-
tial (vs NHE) and then fitted to the equation above.    
Electron paramagnetic resonance (EPR) analysis. Continu-
ous wave EPR spectra were recorded at X-band (~ 9.4 GHz) 
using a Bruker ELEXSYS E500/E580 EPR spectrometer 
(Bruker GmbH, Rheinstetten, Germany). Temperature was 
maintained using an Oxford Instruments ESR900 helium flow 
cryostat coupled to an ITC 503 controller from the same man-
ufacturer. EPR sample tubes were 4 mm Suprasil quartz sup-
plied by Wilmad (Vineland, NJ). Compound I was formed 
using 200 µM protein with 180 µM H2O2 in 50 mM KPi pH 6 
buffer. EPR experiments employed 10 µW microwave power 
(non-saturating), 100 KHz modulation frequency and 1 G (0.1 
mT) modulation amplitude to avoid diminution of any partial-
ly resolved hyperfine coupling. The experimental temperatures 
were as given in the text and figure captions. 
Stopped-flow kinetics. Stopped-flow absorbance experiments 
were performed on an Applied Photophysics SX18 stopped-
flow spectrophotometer (Applied Photophysics Ltd., Leather-
head, UK) equipped with a xenon arc lamp and a 1 cm path 
length in 50 mM KPi pH 6 buffer. To follow the spectra evo-
lution of CcP and CcP Me-His ferric or ferrous to compound I 
and compound II intermediates, respectively, the drive syring-
es were loaded with separate solutions of 16 µM ferric or fer-
rous protein (reduced with minimum dithionite) and stoichio-
metric or 64 µM H2O2.50 Multiple wavelength data were col-
lected at RT using a (PDA) detector and XSCAN software 
(see Figure S6).   
Second-order rate constants for formation of CcP and CcP 
Me-His compound I were derived as follows.  The drive sy-
ringes of the stopped-flow were loaded with separate solutions 
of 4 µM ferric protein and 16, 24, 32 and 40 µM H2O2. Com-
pound I formation was monitored by an increase in absorbance 
at 425 nm at 4°C.  Values are an average of three individual 
measurements (fitted values are given in the Figure S7i) and a 
linear fit of kobs vs [H2O2] was used to derive a bimolecular 
rate constant (k1). 
Second-order rate constants for CcP and CcP Me-His com-
pound I reduction were determined in double mixing stopped 
flow experiments, using an excess of compound I (over cytc) 
to avoid subsequent reduction of compound II. CcP/CcP Me-
His (16 µM) was mixed 1:1 with H2O2 (32 µM) and aged for 1 
s to allow complete compound I formation.  CytcII (3 µM) 
was mixed 1:1 with compound I. Oxidation of ferrous cytc to 
the ferric state was monitored by a reduction in absorbance at 
550 nm. Consistent with previous studies, determination of k2 
under pseudo first order conditions was not possible due to the 
rapid nature of this electron transfer process.24,51  The com-
pound I reduction reaction was kinetically modelled by the 
equation within Figure S7k. Fitting was performed using 
Mathematica 11 (Wolfram Research Inc.) using the NDSolve 
and Findfit functions. The time evolution of [cytcII] was fitted 
by: 𝐴 𝑡 = 𝐴! + 𝛥𝜀!"" × [cyt𝑐](𝑡).  There are 3 fitting pa-
rameters: k, the apparent intrinsic rate constant, described by 
the ODEs; 𝛥𝜀!"" the apparent extinction coefficient difference 
between reactant and products; and A0 the background sample 
absorbance. Experiments were measured under a single set of 
conditions with [CcP]  = 4 µM, [H2O2] = 8 µM and [cytcII] = 
1.5 µM. The model assumes [compound I] = 4 µM at t0 i.e. all 
CcP is converted to compound I prior to the second stopped-
flow push at t0 (the conversion to compound I was shown to be 
complete within 0.2 s in single mixing experiments under 
comparable conditions). Each experiment was performed in 
triplicate and fitted values are given in the Figure S7l. Second-
order rate constants for CcP and CcP Me-His compound II 
reduction were determined in double mixing stopped flow 
experiments. CcP His/CcP Me-His (6.8 µM) was mixed 1:1 
with 6 µM H2O2 and aged for 1 s to allow complete compound 
I formation.  Compound I (3 µM) was subsequently  mixed 1:1 
with 30, 40, 50, 70 µM cytcII. Oxidation of ferrous cytc to the 
ferric state was monitored by a reduction in absorbance at 550 
nm (Figure S7e). Values reported are an average of two-five 
individual measurements and all data were fitted to: 
𝐴!!" = 𝐴! + 𝛥𝐴 𝑒!!! !"#! !! + 𝑒!!!"#!  with k2 fixed to the 
value determined above (fitted values are given in the Figure 
S7j). A linear fit of kobs vs. [cytc] was used to derive a bimo-
lecular rate constant (k3).  
Solvent kinetic isotope effects and pH profiling. KSIE and 
pH profile experiments were performed in a three component 
buffer system (37.5 mM acetic acid, 37. 5 mM MES, 75 mM 
Tris)52,53 with virtually constant ionic strength over a large pH 
range (4.00-7.50).  Deuterated buffers were prepared in 99.9% 
D2O, and pD (pH in D2O) was adjusted according to the fol-
lowing relationship: pD = pHobs + 0.38. Buffers were prepared 
at the following pH/pD values 4.50, 4.75, 5.00, 5.25, 5.50, 
5.75, 6.00, 6.25, 6.50, 6.75. Concentrated stock solutions of 
cytc and H2O2 were prepared in H2O and D2O at pH/pD 6.0 
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and were used for all assays.  Concentrated stock solutions of 
CcP His and CcP Me-His solutions were prepared in a 50:50 
mixture of H2O (pH 6.0) and D2O (pD 6.0) and was used for 
all assays. For pH profiling, assays were performed at a fixed 
concentration of cytc (70 µM). Initial velocities at each pH/pD 
were determined as described above (steady state enzyme ki-
netic assays), using the following assay components: 940 µl of 
appropriate buffer, 10 µl enzyme (1 nM for CcP His and 10 
nM for CcP Me-His), 25 µl cytc (70 µM) and 25 µM H2O2 
(100 µM). The pH was recorded after each measurement. Re-
ported values are corrected for background cytc oxidation in 
the absence of enzyme at the appropriate pH.    
For KSIE at pH/pD 5.0 (37.5 mM acetic acid, 37. 5 mM 
MES, 75 mM Tris) and pH/pD 6.0 (50 mM KPi) steady state 
reactions were performed in triplicate to produce a mean rate 
calculated as moles of cytcII oxidized per mol CcP per second. 
These data were plotted against the relevant cytcII concentra-
tion and fitted using the Michaelis–Menten hyperbolic func-
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